Versant Capital Management, Inc Protagonist Therapeutics, Inc Transaction History
Versant Capital Management, Inc
- $710 Million
- Q3 2025
A detailed history of Versant Capital Management, Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Versant Capital Management, Inc holds 27 shares of PTGX stock, worth $2,097. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27
Previous 29
6.9%
Holding current value
$2,097
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PTGX
# of Institutions
297Shares Held
67.4MCall Options Held
290KPut Options Held
318K-
Farallon Capital Management LLC San Francisco, CA6.17MShares$479 Million1.53% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$447 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$447 Million4.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$339 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.25MShares$252 Million6.36% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $3.81B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...